In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metrika Building U.S. Sales Force For HbA1c In-Office Diabetes Test

This article was originally published in The Gray Sheet

Executive Summary

Metrika has begun assembling a direct U.S. sales force to launch its Digital Response DRx single-use, in-office HbA1c diabetes monitoring test. The company announced FDA 510(k) clearance on July 31.

You may also be interested in...



Metrika

Diabetes diagnostic test developer completes $26 mil. mezzanine round of financing in early April. Funds will be used for ramping up manufacturing of the AlcNOW HbAlc monitoring device (previously known as the DRx HbAlc), and preparing for a full-scale launch. The device was 510(k)-cleared in July 2000 for in-office use and September 2000 for prescription home-use; at the time, the privately held Sunnyvale, California firm said it would wait for additional financing to help build the infrastructure for a product launch (1"The Gray Sheet" Aug. 7, 2000, p. 13). To run the test, a single drop of blood from a finger prick is collected in a supplied pipette; the sample is then mixed with a reagent and inserted into the pager-sized monitor, which displays the level of HbAlc - the amount of hemoglobin bound to glucose - within eight minutes. Funds will also be used for development and marketing of the firm's upcoming microalbumin and cholesterol tests. The transaction was led by Oak Hill Capital Partners, with additional funding provided by Sutter Hill Ventures

Podcast: Scrip’s Asia Team Dissects Pharma’s Response To Coronavirus

Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.

UsernamePublicRestriction

Register

MT013699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel